cyclophosphamide + doxorubicin + vincristine + prednisone + alisertib

This combination therapy, frequently referred to as A-CHOP, integrates alisertib, an investigational and highly selective small molecule inhibitor of Aurora A kinase, with the standard-of-care CHOP chemotherapy backbone (cyclophosphamide, doxorubicin, vincristine, and prednisone). Alisertib disrupts the assembly of the mitotic spindle and chromosome segregation, leading to G2/M cell cycle arrest and apoptosis. Within the CHOP component, cyclophosphamide acts as a nitrogen mustard alkylating agent that cross-links DNA; doxorubicin is an anthracycline that intercalates DNA and inhibits topoisomerase II; vincristine is a vinca alkaloid that binds to tubulin to prevent microtubule polymerization; and prednisone is a synthetic corticosteroid that induces apoptosis in lymphoid cells through glucocorticoid receptor activation. This multi-agent regimen was primarily investigated to improve outcomes in patients with aggressive lymphoid malignancies, specifically peripheral T-cell lymphoma (PTCL), where Aurora A kinase is often overexpressed and associated with poor prognosis.

Other names

alisertib plus CHOPalisertib-CHOP